Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Tripeptide/Hexapeptide Topical and Hybrid Laser Treatment for Acne Scarring

NCT04606134 · View on ClinicalTrials.gov ↗

Study Summary

To evaluate the efficacy of a tripeptide/hexapeptide topical (Alastin Regenerating Skin Nectar with TriHex Technology®) in wound healing and scar reduction following Erbium:YAG hybrid resurfacing laser for acne scarring compared to the standard of post-procedure care consisting of a bland moisturizer.

Interventions

  • DEVICE Hybrid fractional laser
  • OTHER Alastin Regenerating Skin Nectar with TriHex Technology
  • OTHER Cetaphil face cream

Study Locations (1)

New York

  • University of Rochester Medical Center — Rochester

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2020-02-13
Est. Completion 2021-06-18
Phase NA

Sponsor

University of Rochester

437 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04606134

The ClinicalTrials.gov registry entry for NCT04606134 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 437 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Acne Scars - Mixed Atrophic and Hypertrophic appearing as the primary indexed condition, and to 3 interventions — of which Hybrid fractional laser is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04606134 reports 1 study location spanning 1 distinct geographic area — top geographies include New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04606134 about?

NCT04606134 is a clinical study titled "Tripeptide/Hexapeptide Topical and Hybrid Laser Treatment for Acne Scarring". To evaluate the efficacy of a tripeptide/hexapeptide topical (Alastin Regenerating Skin Nectar with TriHex Technology®) in wound healing and scar reduction following Erbium:YAG hybrid resurfacing laser for acne scarring compared to the standard of post-procedure care consisting of a bland moisturize...

What is the current status of trial NCT04606134?

This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2020-02-13. Estimated completion is 2021-06-18.

What conditions does trial NCT04606134 study?

This clinical trial studies the following conditions: Acne Scars - Mixed Atrophic and Hypertrophic. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04606134?

The interventions under investigation include: Hybrid fractional laser (DEVICE), Alastin Regenerating Skin Nectar with TriHex Technology (OTHER), Cetaphil face cream (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04606134?

This trial is sponsored by University of Rochester, which has 437 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04606134 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial